Coordinating Global Capabilities to Support a Gene Therapy Targeting a Rare Neurodegenerative Disorder

An emerging biotech company was searching for an experienced CRO to help their early-phase eff orts to advance a gene therapy that targeted a rare neurodegenerative disease. Learn how multiple teams across Labcorp collaborated to support the biotech's successful IND with GLP toxicology and biodistribution study and CMC services for the sponsor's unique program.

Filed In

Phase I & FIH
Phase IIb
Preclinical & Nonclinical
Rare Disease
Stage (Early, PhI-IIa)
Stage (Late, PhIIb-III)
Therapies - Cell